Macdonald Christie

Prof. Macdonald Christie

Discipline of Pharmacology, The University of Sydney, Sydney, NSW, Australia

Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Cell
Verified
Journal Article
Closed access
LILars Matthias Ittner
Lars Matthias Ittner
YKYazi Ke
Yazi Ke
FDFabien Delerue
Fabien Delerue
MBMian Bi
Mian Bi
AGAmadeus Gladbach
Amadeus Gladbach
JGJürgen Götz
Jürgen Götz

1 December 1988 in Nature
Verified
Journal Article
Closed access
JBJames R. Bunzow
James R. Bunzow
HTHubert H. M. Van Tol
Hubert H. M. Van Tol
DGDavid K. Grandy
David K. Grandy
PAPaul R. Albert
Paul R. Albert
JSJohn Salon
John Salon
OCOlivier Civelli
Olivier Civelli

1 January 2013 in Pharmacological Reviews
Verified
Journal Article
Closed access
PDF file
JWJohn T. Williams
John T. Williams
SISusan L. Ingram
Susan L. Ingram
GHGraeme Henderson
Graeme Henderson
CCCharles Chavkin
Charles Chavkin
MZMark von Zastrow
Mark von Zastrow
MCMacdonald Christie
Macdonald Christie
Morphine and related µ-opioid receptor (MOR) agonists remain among the most effective drugs known for acute relief of severe pain. A major problem in treating painful conditions is that tolerance limits the long-term utility of opioid agonists. Considerable effort has been expended on developing an understanding of the molecular and cellular processes that underlie acute MOR signaling, short-term receptor regulation, and the progression of events that lead to tolerance for different MOR agonists. Although great progress has been made in the past decade, many points of contention and controversy cloud the realization of this progress. This review attempts to clarify some confusion by clearly defining terms, such as desensitization and tolerance, and addressing optimal pharmacological analyses for discerning relative importance of these cellular mechanisms. Cellular and molecular mechanisms regulating MOR function by phosphorylation relative to receptor desensitization and endocytosis are comprehensively reviewed, with an emphasis on agonist-biased regulation and areas where knowledge is lacking or controversial. The implications of these mechanisms for understanding the substantial contribution of MOR signaling to opioid tolerance are then considered in detail. While some functional MOR regulatory mechanisms contributing to tolerance are clearly understood, there are large gaps in understanding the molecular processes responsible for loss of MOR function after chronic exposure to opioids. Further elucidation of the cellular mechanisms that are regulated by opioids will be necessary for the successful development of MOR-based approaches to new pain therapeutics that limit the development of tolerance.

1 January 2001 in Physiological Reviews
Verified
Journal Article
Closed access
PDF file
JWJohn T. Williams
John T. Williams
MCMacdonald Christie
Macdonald Christie
OMOlivier Jacques José Manzoni
Olivier Jacques José Manzoni
Although opioids are highly effective for the treatment of pain, they are also known to be intensely addictive. There has been a massive research investment in the development of opioid analgesics, resulting in a plethora of compounds with varying affinity and efficacy at all the known opioid receptor subtypes. Although compounds of extremely high potency have been produced, the problem of tolerance to and dependence on these agonists persists. This review centers on the adaptive changes in cellular and synaptic function induced by chronic morphine treatment. The initial steps of opioid action are mediated through the activation of G protein-linked receptors. As is true for all G protein-linked receptors, opioid receptors activate and regulate multiple second messenger pathways associated with effector coupling, receptor trafficking, and nuclear signaling. These events are critical for understanding the early events leading to nonassociative tolerance and dependence. Equally important are associative and network changes that affect neurons that do not have opioid receptors but that are indirectly altered by opioid-sensitive cells. Finally, opioids and other drugs of abuse have some common cellular and anatomical pathways. The characterization of common pathways affected by different drugs, particularly after repeated treatment, is important in the understanding of drug abuse.

1 December 1997 in Nature
Verified
Journal Article
Closed access
PDF file
CVChristopher Walter Vaughan
Christopher Walter Vaughan
SIS. L. Ingram
S. L. Ingram
MCM. A. Connor
M. A. Connor
MCMacdonald Christie
Macdonald Christie

1 August 1987 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
RNR A North
R A North
JWJ T Williams
J T Williams
ASA Surprenant
A Surprenant
MCMacdonald Christie
Macdonald Christie
The effects of agonists at mu and delta opioid receptors were compared by measuring membrane currents under voltage clamp from neurons of the rat nucleus locus coeruleus and guinea pig submucous plexus. In each tissue, the appropriate selective agonist (Tyr-D-Ala-Gly-MePhe-Gly-ol for mu receptors in locus coeruleus or Tyr-D-Pen-Gly-Phe-D-Pen for delta receptors in submucous plexus) increased the conductance of an inwardly rectifying potassium conductance and strongly hyperpolarized the membrane. The properties of the potassium conductance affected by the two opioids could not be distinguished. Experiments with intracellular application of guanosine 5'-[gamma-thio]triphosphate indicated that a guanine nucleotide-binding regulatory protein was involved in the coupling between opioid receptor and potassium channel, but there was no evidence for activation of either cAMP-dependent protein kinase or protein kinase C. It is noted that a number of vertebrate neurotransmitter receptors are coupled to potassium channels. The potassium conductance associated with these channels has properties similar to the conductance activated by mu and delta opioids; this family includes the following receptors: acetylcholine M2, norepinephrine alpha 2, dopamine D2, 5-hydroxytryptamine 5-HT1, adenosine A1, gamma-aminobutyric acid GABAB, and somatostatin. It is suggested that this conductance is a conserved neuronal effector coupled to one of the receptor types that mediates the effects of each of several major transmitters. The mu and delta opioid receptors appear to be unusual in that both utilize this same effector mechanism.